Research coverage runs from preclinical mechanism papers to AI-driven peptide discovery. Most of what shows up here lives in Nature, Cell, Science, JAMA, and the abstracts from AACR, ESCMID, AAN, and ESCMID Global.
A few threads keep recurring. Macrocyclic and bicyclic peptides keep getting better at hitting "undruggable" targets — KRAS, beta-catenin, intracellular protein–protein interactions. Antimicrobial peptides have moved from theory to clinical candidates against carbapenem-resistant organisms and biofilms. Cancer peptide vaccines (ELI-002, autogene cevumeran, EVX-01) are producing real survival data. AI design tools — protein language models, transformer architectures, de novo platforms — are starting to generate hits that humans wouldn't.
If you want the lab side without the press releases, this is the right surface. The stories below name the lab, the journal, and the result.
A Nature Communications paper published April 27 mined natural diversity in Viola plants to discover 29 new peptide asparaginyl ligases (PALs) — enzymes that catalyze cyclization of synthetic peptide chains. The work characterizes a pH-dependent cyclization mechanism and defines transferable expression-increasing principles, substantially expanding the enzymatic toolkit available for cyclic peptide drug development. The discovery is timely given the surge of macrocyclic peptide programs at Circle Pharma, Bicycle Therapeutics, and Unnatural Products.
A Nature Communications paper published April 27 introduced DDA-BERT, an end-to-end transformer-based deep learning model for peptide identification in data-dependent acquisition (DDA) proteomics. The model improves peptide identification accuracy across multiple species and outperforms existing methods on HLA immunopeptidomics — directly relevant to neoantigen peptide vaccine discovery for personalized cancer immunotherapy. The work joins the broader 2026 wave of AI-driven peptide tooling captured in this month's ACS Biochemistry and Nature Biotechnology papers.
A Nature Biotechnology paper introduced a user-defined peptide library platform that enables sensitive detection of cancer antigens — relevant for both cancer immunotherapy target identification and neoantigen vaccine design. The platform allows researchers to design peptide pools customized to specific tumor types or HLA profiles, accelerating the antigen-discovery bottleneck in personalized cancer vaccine development. Builds on the same proteomic technology stack advancing across multiple peptide-vaccine programs at BioNTech, Genentech, and emerging neoantigen biotechs.
A Nature Communications paper introduced genetically encoded CRAC (calcium release-activated calcium) channel inhibitory binders — designated CRABs — derived from the ORAI C-terminal tail. Membrane-anchored CRAB variants potently inhibit Ca²⁺ influx and downstream NFAT signaling, offering a peptide-based modulator class for channelopathies, autoimmune disorders, and cancer immunotherapy applications. The mechanism complements existing CRAC channel small-molecule inhibitors and expands the toolkit for precision modulation of calcium signaling.
AJSM published a comprehensive review of injectable peptide therapy for orthopedic and sports medicine, surveying BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu. The authors conclude that while preclinical evidence supports tendon and muscle repair benefits, human trials are minimal — the most-cited BPC-157 human data is a single 12-patient case series with significant methodological flaws. TB-500 and BPC-157 remain WADA-banned. The piece directly addresses surgeons being asked about peptides by patients in the wake of FDA Category 2 changes.
A qualitative research study published in Sports Health (Sage Journals) analyzed Reddit user perspectives on peptide therapy after orthopedic surgery, capturing patient experiences with BPC-157, TB-500, and combination protocols (KLOW, GLOW). The study documents how patients are sourcing peptides outside the regulated medical system, often without physician oversight, and provides one of the few peer-reviewed snapshots of the gray-market peptide community as the FDA July PCAC review approaches.
The American Orthopaedic Society for Sports Medicine published an April 2026 update revisiting the evidence base for peptide therapy in sports medicine. The piece reflects increasing surgeon-side concerns about patients self-administering peptides for recovery from injuries and surgeries, with growing pressure from clinics offering BPC-157 and TB-500 injections. AOSSM's stance remains that current evidence is insufficient to recommend therapeutic peptide use — but the educational push acknowledges the rising clinical reality post-FDA reclassification.
A 2025-2026 PubMed-indexed review (PMID 41490200) consolidates the orthopedics-focused therapeutic peptide literature, covering bone graft peptides (P-15, BMP-2 mimetics), tendon repair peptides (BPC-157, TB-500), cartilage peptides (Cartalax, anti-myostatin agents), and clinical translation challenges. Cerapedics' PearlMatrix P-15 is highlighted as one of the few FDA-cleared peptide-enhanced orthopedic products — context for the company's Vizient supplier deal earlier this week.
An ACS Biochemistry paper published April 10 examined the maturation of AI-designed peptides as tools for biochemistry research and therapeutic development. The work covers computational design of cyclic peptides, antimicrobial peptides, and peptide ligands with novel binding specificities — capturing the moment when machine-learning-driven peptide design has begun delivering candidates competitive with traditional medicinal-chemistry approaches across multiple modality categories.
A January 2026 Frontiers in Cellular and Infection Microbiology review synthesized the case for antimicrobial peptides (AMPs) as the most promising response to antimicrobial resistance, which is responsible for nearly 5 million deaths annually and projected to double by 2050. The review emphasizes that AMPs' rapid, multi-target mechanism — primarily physical membrane disruption — produces significantly lower incidence of resistance emergence than traditional small-molecule antibiotics. The pipeline now exceeds 150 active candidates spanning AI-designed AMPs, lysin-derived peptides, and venom-derived sequences.
Recent reviews and real-world observation studies aggregate the state of peptide-vaccine immunotherapy for glioblastoma. A 2024 Nature Communications real-world observational study reported clinically meaningful outcomes for personalized peptide vaccines; the UCPVax + temozolomide trial (NCT04280848) showed 97% anti-TERT immune response, 48% epitope spread, median OS 17.9 months, and 26% alive at 2 years. The peptide-vaccine modality is one of multiple approaches (mRNA, dendritic cell, neoantigen) advancing alongside immune checkpoint blockade.
A peptide skincare research update highlighted Acetyl Heptapeptide-9 paired with colloidal gold nanoparticle delivery technology — clinical data showed 55% wrinkle reduction within 4 weeks and 20× the collagen-stimulating potency of the free peptide. The case illustrates how 2026's peptide skincare innovation is shifting from new sequence discovery toward advanced delivery vehicles (gold nanoparticles, lipid carriers, microemulsions) that solve the longstanding skin penetration problem for hydrophilic peptides.
A Nature Communications paper introduced a broad-spectrum macrocyclic peptide inhibitor designed for intranasal administration that protects against multiple SARS-CoV-2 Omicron variants in preclinical models. The work expands the macrocyclic peptide modality beyond oncology into respiratory antivirals, where peptide stability and tissue penetration challenges have historically limited clinical translation. Published as Nature Communications article s41467-026-68462-9.
A Nature Communications paper introduced CycloSEL (Cyclic Self-Encoded Libraries), an end-to-end workflow that screens synthetic macrocycle libraries enriched in drug-like 'beyond rule of five' features using affinity selections and tandem mass spectrometry — eliminating the genetic-barcode requirement of traditional macrocyclic peptide discovery. The team validated the approach against the oncology target carbonic anhydrase IX with a 16-million-member library, achieving robust enrichment and accurate identification of true binders. The platform shifts peptide drug discovery toward small molecule-like drug-likeness optimization from day one.
A recent PubMed-indexed study reports that Mu-17 — a novel antimicrobial peptide designed using a bio-inspired approach based on scorpion AMP leucine-zipper-like motifs — showed both antimicrobial and anticancer activity with reduced toxicity. Mu-17 inhibited breast cancer cell proliferation with IC50 of 13 µM and exhibited remarkably low hemolytic activity (18% at 100 µM). The work adds to the emerging category of venom-derived peptides with dual therapeutic applications, complementing ongoing AI-driven antimicrobial peptide discovery efforts disclosed at AACR 2026 and ESCMID 2026.
Lirum Therapeutics announced preclinical data at AACR 2026 demonstrating antitumor activity of LX-101, an IGF-1R–targeted peptide-payload conjugate, in Ewing sarcoma patient-derived xenograft models. As a monotherapy, LX-101 showed meaningful single-agent activity and demonstrated synergy when combined with PI3K or mTOR inhibition. The compound was previously granted FDA "Study May Proceed" authorization for inclusion in the RAPID platform clinical trial for relapsed/refractory Ewing sarcoma and desmoplastic small round cell tumor (DSRCT).
Avacta Therapeutics presented April 21 data at AACR 2026 showing its FAP-enabled peptide-drug conjugate AVA6103, which delivers exatecan via the pre|CISION® platform, achieved a Tumor Selectivity Index three times higher than marketed ADC Enhertu in preclinical models, with tumor Cmax more than one log higher. AVA6103 entered the Phase 1 FOCUS-01 trial (NCT07454642) in March 2026 with initial clinical readout expected later this year.
AlphaGen Therapeutics presented preclinical data at AACR 2026 (April 22) showing its novel macrocyclic peptide-based alpha-emitter radioligand [212Pb]Pb-AG1206 binds fibroblast activation protein with picomolar affinity, achieving rapid tumor accumulation, renal clearance, and a high tumor-to-kidney ratio. A sister candidate [212Pb]Pb-AG1002 targets SSTR2 as a non-agonist alpha therapy for neuroendocrine tumors.